{"id":5022,"date":"2025-03-21T19:26:28","date_gmt":"2025-03-21T18:26:28","guid":{"rendered":"https:\/\/jegharkraeft.dk\/?p=5022"},"modified":"2026-02-05T20:42:41","modified_gmt":"2026-02-05T19:42:41","slug":"tyrosinkinasehaemmere","status":"publish","type":"post","link":"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/","title":{"rendered":"Tyrosinkinaseh\u00e6mmere. Crizotinib (Xalkori), Dasatinib (Sprycel), Erlotinib (Tarceva), (Gefitinib (Iressa)), Imatinib (Gleevec), (Lapatinib (Tykerb)), Nilotinib (Tasigna), Sorafenib (Nexavar), Sunitinib (Sutent)"},"content":{"rendered":"\n<div class=\"wp-block-group alignfull is-style-section-5 has-contrast-color has-base-background-color has-text-color has-background has-link-color wp-elements-7e9ba63a6c3e2d48600340c869748380 has-global-padding is-layout-constrained wp-block-group-is-layout-constrained is-style-section-5--2\" id=\"menu\" style=\"margin-top:0;margin-bottom:0;padding-top:var(--wp--preset--spacing--50);padding-bottom:var(--wp--preset--spacing--50)\">\n<div class=\"wp-block-columns alignwide is-layout-flex wp-container-core-columns-is-layout-ca2dd60b wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<h2 class=\"wp-block-heading has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-7dcb782fe06e372bd968f4bf90d58c0a\"><span class=\"ez-toc-section\" id=\"Behandlinger\"><\/span><a href=\"https:\/\/jegharkraeft.dk\/kraeft-behandlinger\">Behandlinger <\/a><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<div class=\"wp-block-group has-custom-interne-links-color has-text-color has-link-color wp-elements-a064263a9de053c2235caa3bc8547ea6 has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\">\n<h4 class=\"wp-block-heading has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-49b301964cbfab50924982081a6d1c63\"><a href=\"https:\/\/jegharkraeft.dk\/traditionelle-kraeftbehandlinger-oversigt#traditionellebehandlingertekst\">Traditionelle Behandlinger Oversigt<\/a><a href=\"https:\/\/jegharkraeft.dk\/traditionelle-kraeftbehandlinger-oversigt#traditionellebehandlingertekst\"><\/a><a href=\"https:\/\/jegharkraeft.dk\/alternative-oversigt\"><\/a><\/h4>\n\n\n\n<p class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-d07406a00d8f6420b2073bafbd0d05a6 wp-block-paragraph\"><a href=\"https:\/\/jegharkraeft.dk\/traditionelle-behandlinger\">0. Traditionelle Behandlinger Alment<\/a><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-60aa910da5284a603c7fa5ea0e6431c9\"><a href=\"https:\/\/jegharkraeft.dk\/genterapi-tra-1\/\">Prim\u00e6re Behandlingsformer<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-fc470c648162881ae48582717fdedf7d\"><a href=\"https:\/\/jegharkraeft.dk\/minimer-kemo\">Supportive Behandlinger<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-a7b1777caf915a9506b5da491c5ab820\"><a href=\"https:\/\/jegharkraeft.dk\/cyberknife\">Specifikke Behandlinger og teknikker<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-c636869deb007046657d11c8b2fb2f29\"><a href=\"https:\/\/jegharkraeft.dk\/genterapi-1\">S\u00e6rlige Kategorier<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/jegharkraeft.dk\/antimetabolitter-laegemidler\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-hvid-tekst-color\">L\u00e6gemiddelbehandling<\/mark><\/a>\n<ul class=\"wp-block-list\">\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-4a892c6cef3e7fe82f18a27de62f7b2e\"><a href=\"https:\/\/jegharkraeft.dk\/antimetabolitter-laegemidler\">5.A Kemoterapi<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-5ca910f8f6040db5d8927f0cc31cdb05\"><a href=\"https:\/\/jegharkraeft.dk\/hormonterapi-1\">5.B Hormonbehandling<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-bafac9b29b2e7081094b8ecdd106aa04\"><a href=\"https:\/\/jegharkraeft.dk\/car-t-behandling\">5.C Immun-onkologi<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/jegharkraeft.dk\/enhertu\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-hvid-tekst-color\">5.D M\u00e5lrettet terapi<\/mark><\/a>\n<ul class=\"wp-block-list\">\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-aff51506a13f56b4901ed8157c7879e4\"><a href=\"https:\/\/jegharkraeft.dk\/enhertu\">Enhertu<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-412dd074b9110f66a628338b243afc64\"><a href=\"https:\/\/jegharkraeft.dk\/enzalutamid\">Enzalutamid<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-0ce37051b51c5803e8778e4490c0cc3e\"><a href=\"https:\/\/jegharkraeft.dk\/monoklonale-antistoffer\">Monoklonale antistoffer<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-e0e290f90e7c4ca8a67040eb4e61182a\"><a href=\"https:\/\/jegharkraeft.dk\/phesgo\/\">Phesgo<\/a><\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-e9efc074566f4be021ee42e416810914\"><a href=\"https:\/\/jegharkraeft.dk\/trastuzumab-tdm1\">Trastuzumab (TDM1)<\/a><\/li>\n\n\n\n<li class=\"has-custom-her-st-r-du-color has-text-color has-link-color wp-elements-6cf44ce6c0377852c4cdaf3f2e6cfe0b\"><a href=\"#tyrosinkinase-haemmer\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-her-st-r-du-color\">Tyrosinkinaseh\u00e6mmere (scroll ned)<\/mark><\/a><\/li>\n<\/ul>\n<\/li>\n\n\n\n<li class=\"has-custom-int-link-p-sort-1-color has-text-color has-link-color wp-elements-8605df5e02ec23116b26075f98d31870\"><a href=\"https:\/\/jegharkraeft.dk\/angiogenesehaemmere\">5.E Andre pr\u00e6parater<\/a><\/li>\n<\/ul>\n<\/li>\n<\/ol>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:50%\">\n<figure class=\"wp-block-image aligncenter size-full is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1600\" height=\"1619\" src=\"http:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/02\/bTyrosinkinasehaemmere.jpg\" alt=\"Tyrosinkinaseh\u00e6mmere symboliseret ved lilla blomsterstande p\u00e5 mark.\" class=\"wp-image-4389\" style=\"aspect-ratio:3\/2;object-fit:cover;width:550px\" srcset=\"https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/02\/bTyrosinkinasehaemmere.jpg 1600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/02\/bTyrosinkinasehaemmere-100x100.jpg 100w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/02\/bTyrosinkinasehaemmere-600x607.jpg 600w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/02\/bTyrosinkinasehaemmere-296x300.jpg 296w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/02\/bTyrosinkinasehaemmere-1012x1024.jpg 1012w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/02\/bTyrosinkinasehaemmere-768x777.jpg 768w, https:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/02\/bTyrosinkinasehaemmere-1518x1536.jpg 1518w\" sizes=\"auto, (max-width: 1600px) 100vw, 1600px\" \/><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group alignfull is-style-default has-global-padding is-layout-constrained wp-container-core-group-is-layout-b040ace0 wp-block-group-is-layout-constrained has-background\" style=\"margin-top:0;margin-bottom:0;padding-top:var(--wp--preset--spacing--60);padding-right:var(--wp--preset--spacing--20);padding-bottom:var(--wp--preset--spacing--60);padding-left:var(--wp--preset--spacing--20);background-image:url(&apos;http:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/02\/bTyrosinkinasehaemmere.jpg&apos;);background-size:cover;\">\n<div class=\"gb-element-906497af\">\n<h1 class=\"wp-block-heading\" id=\"tyrosinkinase-haemmer\"><span class=\"ez-toc-section\" id=\"Tyrosinkinasehaemmere_%E2%80%93_Laegemiddelbehandling_mod_kraeft\"><\/span>Tyrosinkinaseh\u00e6mmere &#8211; L\u00e6gemiddelbehandling mod kr\u00e6ft<span class=\"ez-toc-section-end\"><\/span><\/h1>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Herunder omtales:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Crizotinib (Xalkori)<\/li>\n\n\n\n<li>Dasatinib (Sprycel)<\/li>\n\n\n\n<li>Erlotinib (Tarceva)<\/li>\n\n\n\n<li>(Gefitinib (Iressa))<\/li>\n\n\n\n<li>Imatinib (Gleevec)<\/li>\n\n\n\n<li>(Lapatinib (Tykerb))<\/li>\n\n\n\n<li>Nilotinib (Tasigna)<\/li>\n\n\n\n<li>Sorafenib (Nexavar)<\/li>\n\n\n\n<li>Sunitinib (Sutent)<\/li>\n<\/ul>\n\n\n\n<h4 class=\"wp-block-heading\">Hvad er Tyrosinkinaseh\u00e6mmere<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Tyrosinkinaseh\u00e6mmere (TKI&#8217;er) repr\u00e6senterer en milep\u00e6l inden for kr\u00e6ftbehandling, der tilbyder en mere m\u00e5lrettet og pr\u00e6cis tilgang til at bek\u00e6mpe kr\u00e6ft. De virker ved at blokere aktiviteten af tyrosinkinaser, en familie af enzymer, der spiller en kritisk rolle i reguleringen af cellev\u00e6kst, proliferation, differentiering og overlevelse. I kr\u00e6ftceller kan tyrosinkinaser v\u00e6re overaktive eller dysregulerede, hvilket f\u00f8rer til ukontrolleret celledeling og tumorudvikling.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Tyrosinkinasehaemmernes_molekylaere_mekanismer\"><\/span>Tyrosinkinaseh\u00e6mmernes molekyl\u00e6re mekanismer<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">For at forst\u00e5 TKI&#8217;ernes virkningsmekanisme er det n\u00f8dvendigt at dykke ned i tyrosinkinase-enzymernes funktion og deres rolle i cellul\u00e6re signalveje.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signaltransduktionens_dirigenter\"><\/span><strong>Signaltransduktionens dirigenter<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Tyrosinkinaser er en type enzymer, der katalyserer fosforylering af tyrosinrester p\u00e5 proteiner. Fosforylering er en proces, hvor en fosfatgruppe tilf\u00f8jes til et protein, hvilket kan \u00e6ndre dets aktivitet, struktur og interaktioner med andre proteiner. Tyrosinkinaser fungerer som &#8220;on\/off-switches&#8221; i cellul\u00e6re signalveje, der regulerer en bred vifte af cellul\u00e6re processer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Signaltransduktion_og_kraeft\"><\/span><strong>Signaltransduktion og kr\u00e6ft<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Cellul\u00e6re signalveje er komplekse netv\u00e6rk af proteiner, der transmitterer signaler fra cellens overflade til kernen og andre cellul\u00e6re komponenter. Disse signaler regulerer cellev\u00e6kst, proliferation, differentiering og overlevelse. I kr\u00e6ftceller kan mutationer eller overekspression af tyrosinkinaser f\u00f8re til dysregulering af signalveje og ukontrolleret cellev\u00e6kst.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"TKIernes_indgriben_i_signaltransduktion\"><\/span><strong>TKI&#8217;ernes indgriben i signaltransduktion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">TKI&#8217;er er designet til at binde sig til tyrosinkinaser og blokere deres aktivitet. Denne binding forhindrer fosforylering af downstream-proteiner i signalvejen og h\u00e6mmer dermed de signaler, der driver kr\u00e6ftcellernes v\u00e6kst og overlevelse.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Hvordan_virker_tyrosinkinasehaemmere\"><\/span>Hvordan virker tyrosinkinaseh\u00e6mmere<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Tyrosinkinaser er enzymer, der tilf\u00f8jer en fosfatgruppe til tyrosinrester p\u00e5 proteiner. Denne proces, kaldet fosforylering, fungerer som en &#8220;t\u00e6nd\/sluk-knap&#8221; for mange cellul\u00e6re processer, herunder cellev\u00e6kst, -deling, -differentiering og -overlevelse.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Arsager_til_overaktivitet_af_tyrosinkinaser_i_kraeftceller\"><\/span><strong>\u00c5rsager til overaktivitet af tyrosinkinaser i kr\u00e6ftceller:<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Genmutationer<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mutationer i gener, der koder for tyrosinkinaser, kan f\u00f8re til \u00f8get aktivitet eller produktion af enzymet.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Overekspression<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kr\u00e6ftceller kan producere for meget af en bestemt tyrosinkinase.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Aktivering af signalveje<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Signalveje, der involverer tyrosinkinaser, kan v\u00e6re overaktive i kr\u00e6ftceller.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">TKI&#8217;er binder sig til tyrosinkinaser og blokerer deres aktivitet. Dette forhindrer fosforylering af downstream-proteiner og h\u00e6mmer dermed de signaler, der driver kr\u00e6ftcellernes v\u00e6kst og overlevelse.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Effekt_pa_kraeftceller\"><\/span>Effekt p\u00e5 kr\u00e6ftceller<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">TKI&#8217;er har en m\u00e5lrettet effekt p\u00e5 kr\u00e6ftceller, der udtrykker specifikke tyrosinkinaser:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>H\u00e6mning af cellev\u00e6kst og -deling<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">TKI&#8217;er blokerer de signaler, der driver kr\u00e6ftcellernes v\u00e6kst og deling.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Inducering af apoptose<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">TKI&#8217;er kan udl\u00f8se programmeret celled\u00f8d (apoptose) i kr\u00e6ftceller ved at forstyrre signaler, der er n\u00f8dvendige for cellernes overlevelse.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>H\u00e6mning af angiogenese<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nogle TKI&#8217;er kan h\u00e6mme dannelsen af nye blodkar (angiogenese), som kr\u00e6fttumorer har brug for for at vokse.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>H\u00e6mning af metastase<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">TKI&#8217;er kan h\u00e6mme kr\u00e6ftcellernes evne til at sprede sig til andre dele af kroppen (metastase).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Effekt_pa_raske_celler\"><\/span>Effekt p\u00e5 raske celler<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">TKI&#8217;er kan ogs\u00e5 p\u00e5virke raske celler, der udtrykker de samme tyrosinkinaser. Dette kan f\u00f8re til en r\u00e6kke bivirkninger:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hudreaktioner<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Udsl\u00e6t, kl\u00f8e, t\u00f8r hud, h\u00e5nd-fod-syndrom (r\u00f8dme, h\u00e6velse og smerter i h\u00e6nder og f\u00f8dder).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gastrointestinale bivirkninger<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kvalme, opkastning, diarr\u00e9, forstoppelse.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hjertebivirkninger<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Forl\u00e6nget QT-interval (en forstyrrelse i hjerterytmen), hjertesvigt.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Leverbivirkninger<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Forh\u00f8jede leverenzymer, leverskader.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Lungebivirkninger<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lungefibrose (ardannelse i lungerne).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00d8jenbivirkninger<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">T\u00f8rre \u00f8jne, sl\u00f8ret syn.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bivirkninger\"><\/span>Bivirkninger<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Selvom tyrosinkinaseh\u00e6mmere (TKI&#8217;er) er effektive til behandling af visse kr\u00e6ftformer, kan de, som al anden medicin, for\u00e5rsage bivirkninger. Disse bivirkninger varierer afh\u00e6ngigt af den specifikke TKI, dosis og den individuelle patients helbredstilstand.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Her er en oversigt over nogle af de mest almindelige bivirkninger forbundet med TKI&#8217;er:<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Almindelige_bivirkninger\"><\/span>Almindelige bivirkninger:<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hudreaktioner<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Udsl\u00e6t, kl\u00f8e, t\u00f8r hud, aknelignende udsl\u00e6t, \u00e6ndringer i hudpigmentering.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mave-tarm-problemer<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Diarr\u00e9, kvalme, opkastning, mavesmerter, forstoppelse, appetitl\u00f8shed.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Tr\u00e6thed<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">En f\u00f8lelse af udmattelse og mangel p\u00e5 energi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>V\u00e6skeophobning<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">H\u00e6velse i benene, anklerne eller f\u00f8dderne (\u00f8dem).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hovedpine.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Muskelsmerter eller -kramper.<\/li>\n\n\n\n<li>H\u00e5rtab.<\/li>\n\n\n\n<li>Negleforandringer.<\/li>\n\n\n\n<li>Mundt\u00f8rhed.<\/li>\n\n\n\n<li>\u00c6ndringer i smagsoplevelse.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Leverp\u00e5virkning<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Forh\u00f8jede leverenzymer, gulsot.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Mindre_almindelige_men_alvorlige_bivirkninger\"><\/span>Mindre almindelige, men alvorlige bivirkninger<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hjerteproblemer<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Hjerteinsufficiens, forl\u00e6nget QT-interval (en hjerterytmeforstyrrelse).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Lungeproblemer<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Lungefibrose (ardannelse i lungerne), lungebet\u00e6ndelse.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bl\u00f8dningsproblemer<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nedsat antal blodplader, \u00f8get risiko for bl\u00f8dning.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Infektioner<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nedsat immunforsvar, \u00f8get risiko for infektioner.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nyreproblemer<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Nedsat nyrefunktion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>\u00d8jenproblemer<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sl\u00f8ret syn, \u00f8jenirritation.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Neurologiske problemer<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Perifer neuropati (f\u00f8lelsesl\u00f8shed, prikken eller smerter i h\u00e6nder og f\u00f8dder), svimmelhed, hovedpine.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Handtering_af_bivirkninger\"><\/span>H\u00e5ndtering af bivirkninger<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Mange bivirkninger kan h\u00e5ndteres med medicin eller livsstils\u00e6ndringer.<\/li>\n\n\n\n<li>Det er vigtigt at informere din l\u00e6ge om eventuelle bivirkninger, du oplever.<\/li>\n\n\n\n<li>L\u00e6gen kan justere dosis eller ordinere medicin til at lindre bivirkninger.<\/li>\n<\/ul>\n\n\n\n<ul class=\"wp-block-list\">\n<li>I nogle tilf\u00e6lde kan det v\u00e6re n\u00f8dvendigt at afbryde behandlingen midlertidigt eller permanent.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Resistensmekanismer\"><\/span>Resistensmekanismer<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Kr\u00e6ftceller kan udvikle resistens over for TKI&#8217;er over tid. Der er forskellige mekanismer, der kan bidrage til resistens:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Mutationer i tyrosinkinase-genet<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Mutationer i det gen, der koder for tyrosinkinase-enzymet, kan forhindre TKI&#8217;en i at binde sig effektivt.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Amplifikation af tyrosinkinase-genet<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kr\u00e6ftceller kan \u00f8ge antallet af kopier af tyrosinkinase-genet, hvilket f\u00f8rer til overekspression af enzymet og reduceret f\u00f8lsomhed over for TKI&#8217;en.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Aktivering af alternative signalveje<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kr\u00e6ftceller kan aktivere alternative signalveje, der omg\u00e5r den blokerede tyrosinkinase og forts\u00e6tter med at drive cellev\u00e6kst.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Overvindelse_af_resistens\"><\/span>Overvindelse af resistens<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Der forskes i at udvikle nye TKI&#8217;er og kombinationsbehandlinger for at overvinde resistens. Nogle strategier inkluderer:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>N\u00e6ste generations TKI&#8217;er<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Udvikling af TKI&#8217;er, der er effektive mod resistente mutationer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kombinationsterapi<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kombination af TKI&#8217;er med andre behandlinger, s\u00e5som kemoterapi, str\u00e5lebehandling eller immunterapi.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>M\u00e5lrettet behandling af resistensmekanismer<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Udvikling af l\u00e6gemidler, der specifikt h\u00e6mmer resistensmekanismer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Typer_af_tyrosinkinasehaemmere\"><\/span>Typer af tyrosinkinaseh\u00e6mmere<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Der findes forskellige typer af TKI&#8217;er, der er klassificeret efter deres struktur, selektivitet og virkningsmekanisme:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Type I-h\u00e6mmere<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Binder sig til den aktive konformation af tyrosinkinase-enzymet.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Type II-h\u00e6mmere<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Binder sig til den inaktive konformation af tyrosinkinase-enzymet.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Allosteriske h\u00e6mmere<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Allosteriske h\u00e6mmere betyder binding \u00e9t sted \u00e6ndrer proteinets funktion et andet sted. Disse h\u00e6mmere binder sig til et andet sted p\u00e5 enzymet end det aktive sted og inducerer konformations\u00e6ndringer, der h\u00e6mmer enzymaktiviteten.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kovalente (elektrondeling) h\u00e6mmere<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Danner en irreversibel binding til tyrosinkinase-enzymet.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Eksempler_pa_tyrosinkinasehaemmere\"><\/span>Eksempler p\u00e5 tyrosinkinaseh\u00e6mmere<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Eksempler p\u00e5 TKI&#8217;er og deres anvendelse i kr\u00e6ftbehandling<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Her er en mere detaljeret beskrivelse af nogle almindelige TKI&#8217;er og deres anvendelse i behandlingen af forskellige kr\u00e6ftformer:<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"1_Imatinib_Gleevec\"><\/span>1. Imatinib (Gleevec)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>M\u00e5l: BCR-ABL tyrosinkinase<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kr\u00e6ftformer:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kronisk myeloid leuk\u00e6mi (CML)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Imatinib er en revolutionerende behandling for CML, der har forvandlet sygdommen fra en d\u00f8delig til en kronisk sygdom for de fleste patienter. Den binder sig specifikt til BCR-ABL-fusionsproteinet, der er karakteristisk for CML, og h\u00e6mmer dets aktivitet.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Akut lymfoblastisk leuk\u00e6mi (ALL)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Imatinib anvendes ogs\u00e5 til behandling af ALL med Philadelphia-kromosomet, der har en lignende genetisk abnormalitet som CML.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gastrointestinale stromale tumorer (GIST)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Imatinib kan ogs\u00e5 bruges til behandling af GIST med specifikke mutationer i KIT-genet.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"2_Gefitinib_Iressa_og_Erlotinib_Tarceva\"><\/span>2. Gefitinib (Iressa) og Erlotinib (Tarceva)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>M\u00e5l: EGFR tyrosinkinase<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kr\u00e6ftformer:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Ikke-sm\u00e5cellet lungekr\u00e6ft (NSCLC)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Gefitinib og Erlotinib er effektive til behandling af NSCLC med specifikke mutationer i EGFR-genet, der g\u00f8r kr\u00e6ftcellerne mere f\u00f8lsomme over for disse l\u00e6gemidler.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pancreascancer<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Erlotinib kan anvendes i kombination med gemcitabin til behandling af avanceret pancreascancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"3_Sunitinib_Sutent\"><\/span>3. Sunitinib (Sutent)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>M\u00e5l: Flere tyrosinkinaser, herunder VEGFR, PDGFR og KIT.<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kr\u00e6ftformer:<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nyrekr\u00e6ft<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sunitinib er en standardbehandling for avanceret nyrekr\u00e6ft. Ved at h\u00e6mme VEGFR blokerer det angiogenese (dannelse af nye blodkar), som er essentiel for tumorv\u00e6kst.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Gastrointestinale stromale tumorer (GIST)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sunitinib anvendes til behandling af GIST, der ikke responderer p\u00e5 imatinib eller har spredt sig.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pancreasneuroendokrine tumorer (pNET)<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Sunitinib kan bruges til behandling af avancerede pNET.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"4_Andre_TKIer\"><\/span>4. Andre TKI&#8217;er<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dasatinib_Sprycel_og_Nilotinib_Tasigna\"><\/span>Dasatinib (Sprycel) og Nilotinib (Tasigna)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Anvendes til behandling af CML, is\u00e6r hos patienter, der er resistente eller intolerante over for imatinib.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sorafenib_Nexavar\"><\/span>Sorafenib (Nexavar)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">H\u00e6mmer flere tyrosinkinaser, herunder VEGFR, PDGFR og RAF-kinaser. Anvendes til behandling af leverkr\u00e6ft, nyrekr\u00e6ft og differentieret thyroideacancer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Lapatinib_Tykerb\"><\/span>Lapatinib (Tykerb)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">H\u00e6mmer b\u00e5de EGFR og HER2 tyrosinkinaser. Anvendes til behandling af HER2-positiv brystkr\u00e6ft.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Crizotinib_Xalkori\"><\/span>Crizotinib (Xalkori)<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">H\u00e6mmer ALK tyrosinkinase. Anvendes til behandling af NSCLC med ALK-rearrangementer.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bemaerk\"><\/span>Bem\u00e6rk<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">TKI&#8217;er er m\u00e5lrettede terapier, der kun er effektive hos patienter med kr\u00e6ftformer, der har specifikke genetiske \u00e6ndringer eller overudtrykker bestemte tyrosinkinaser.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Valget af TKI afh\u00e6nger af kr\u00e6fttypen, patientens individuelle karakteristika og eventuelle tidligere behandlinger.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bivirkninger<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">TKI&#8217;er kan have bivirkninger, der varierer afh\u00e6ngigt af det specifikke l\u00e6gemiddel. Almindelige bivirkninger inkluderer diarr\u00e9, hududsl\u00e6t, tr\u00e6thed og hypertension.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Aspekter_ved_behandling\"><\/span>Aspekter ved behandling<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Molekyl\u00e6r testning<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For at identificere patienter, der kan have gavn af TKI&#8217;er, er det ofte n\u00f8dvendigt at udf\u00f8re molekyl\u00e6r testning for at identificere specifikke mutationer eller overekspression af tyrosinkinaser.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Resistens<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kr\u00e6ftceller kan udvikle resistens over for TKI&#8217;er over tid. Der forskes i at udvikle nye TKI&#8217;er og kombinationsbehandlinger for at overvinde resistens.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bivirkningsh\u00e5ndtering<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Det er vigtigt at overv\u00e5ge patienter for bivirkninger og behandle dem hurtigt og effektivt.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Konklusion\"><\/span>Konklusion<span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Tyrosinkinaseh\u00e6mmere (TKI&#8217;er) er en klasse af l\u00e6gemidler, der blokerer aktiviteten af tyrosinkinaser, enzymer der spiller en rolle i cellev\u00e6kst og -deling. Ved at h\u00e6mme disse enzymer, kan TKI&#8217;er bremse den ukontrollerede cellev\u00e6kst, der ses i kr\u00e6ft. TKI&#8217;er anvendes i behandlingen af forskellige kr\u00e6ftformer, herunder leuk\u00e6mi, lungekr\u00e6ft og nyrekr\u00e6ft. Det er dog vigtigt at huske, at TKI&#8217;er er m\u00e5lrettede terapier, der kun er effektive hos patienter med specifikke genetiske \u00e6ndringer, og at de kan have bivirkninger.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Fremtiden for TKI&#8217;er<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Forskningen i TKI&#8217;er er i konstant udvikling, og der er l\u00f8bende nye l\u00e6gemidler under udvikling og afpr\u00f8vning. Fremtidens TKI&#8217;er forventes at v\u00e6re endnu mere m\u00e5lrettede og effektive med f\u00e6rre bivirkninger.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Denne information er kun til generel viden og erstatter ikke professionel medicinsk r\u00e5dgivning. Det er altid vigtigt at tale med din l\u00e6ge om din specifikke situation og behandling.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Statistikker\"><\/span><a href=\"#tyrosinkinasehaemmer-statistik\">Statistikker<\/a><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Disse statistikker er baseret p\u00e5 gennemsnitlige resultater fra store grupper af patienter. Den individuelle effekt af tyrosinkinaseh\u00e6mmere kan variere betydeligt afh\u00e6ngigt af kr\u00e6fttype, stadie, patientens generelle sundhedstilstand og andre faktorer.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Bem\u00e6rk<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">De n\u00e6vnte tal stammer fra Gemini Advanced. Jeg har ingen mulighed for at tjekke p\u00e5lideligheden. Men den er s\u00e6dvanligvis p\u00e5lidelig.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Se ogs\u00e5 <a href=\"https:\/\/jegharkraeft.dk\/hormonterapi\"><strong>Hormonbehandling<\/strong><\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Se ogs\u00e5 <a href=\"https:\/\/jegharkraeft.dk\/antioestrogen-naturligt\"><strong>Naturlige antihormoner<\/strong><\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forts\u00e6ttes&#8230;<\/strong><\/p>\n\n\n\n<p class=\"has-custom-menu-links-color has-text-color has-link-color wp-elements-ecc20eb682e01fea2769c298cbd834ce wp-block-paragraph\"><strong><a href=\"#menu\" data-type=\"internal\" data-id=\"#diagnose\">(Til menu)<\/a><\/strong><a href=\"https:\/\/jegharkraeft.dk\/antioestrogen-naturligt\"><\/a><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Links<\/h4>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-96afc5941676e6c30963424e7ebb6cb6 wp-block-paragraph\"><a href=\"https:\/\/www.google.com\/search?q=Tyrosinkinaseh%C3%A6mmer&amp;rlz=1C1ONGR_enDK1116DK1116&amp;oq=Tyrosinkinaseh%C3%A6mmer&amp;gs_lcrp=EgZjaHJvbWUyCQgAEEUYORiABDIHCAEQABiABDIKCAIQABiABBiiBDIKCAMQABiABBiiBDIGCAQQRRg90gEHNDkyajBqN6gCALACAA&amp;sourceid=chrome&amp;ie=UTF-8\" target=\"_blank\" rel=\"noreferrer noopener\">Tyrosinkinaseh\u00e6mmere \u00f8ger risikoen for QTc-forl\u00e6ngelse<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(Ugeskrift for L\u00e6ger)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-79aec92bf2554c62a26667aa2be3a946 wp-block-paragraph\"><a href=\"https:\/\/dagensmedicin.dk\/tyrosinkinasehaemmer-forlaenger-progressionsfri-overlevelse-ved-sjaeldne-neuroendokrine-tumorer\/\" target=\"_blank\" rel=\"noreferrer noopener\">Tyrosinkinaseh\u00e6mmer forl\u00e6nger progressionsfri overlevelse ved sj\u00e6ldne neuroendokrine tumorer<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(Dagens Medicin)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-f6e1c207b66883da68fd9ae7f8e05102 wp-block-paragraph\"><a href=\"https:\/\/netdoktor.dk\/kraeft\/leukaemi\/sygdomme\/medicinsk-behandling-af-cml-kronisk-myeloid-leukami\/\" target=\"_blank\" rel=\"noreferrer noopener\">Medicinsk behandling af CML (kronisk myeloid leuk\u00e6mi) <\/a><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(Netdoktor.dk)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-e062362f2f934aa1aa501da368de6037 wp-block-paragraph\"><a href=\"https:\/\/www.herlevhospital.dk\/undersoegelse-og-behandling\/find-undersoegelse-og-behandling\/Sider\/Crizotinib---Xalkori-behandling-med--23411.aspx\" target=\"_blank\" rel=\"noreferrer noopener\">Crizotinib &#8211; Xalkori, behandling med<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(Herlev Hospital)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-e24f610da0938df7581d7e9e3e9aa0be wp-block-paragraph\"><a href=\"https:\/\/laegemiddelstyrelsen.dk\/da\/nyheder\/2022\/xalkori-crizotinib-synsforstyrrelser,-herunder-risiko-for-alvorligt-synstab,-og-behov-for-monitorering-hos-paediatriske-patienter\/\" target=\"_blank\" rel=\"noreferrer noopener\">Xalkori (crizotinib): Synsforstyrrelser, herunder risiko for alvorligt synstab, og behov for monitorering hos p\u00e6diatriske patienter<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(L\u00e6gemiddelstyrelsen)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-006fdcecb4ea9d4190a33716ba1670b6 wp-block-paragraph\"><a href=\"https:\/\/min.medicin.dk\/medicin\/praeparater\/4089\" target=\"_blank\" rel=\"noreferrer noopener\">Sprycel<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(Medicin.dk)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-b4e28ca2a32562b82d52d54d26791fd0 wp-block-paragraph\"><a href=\"https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160715135210\/anx_135210_da.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Dasatinib &#8211; SPRYCEL, INN<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(European Commission)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-53449a3fc8da632212cec025c5ea0fcd wp-block-paragraph\"><a href=\"https:\/\/xnet.dkma.dk\/indlaegsseddel\/PdfFileServlet?formulationid=6534&amp;lang=da\" target=\"_blank\" rel=\"noreferrer noopener\">Dasatinib &#8211; Sprycel, INN<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(L\u00e6gemiddelstyrelsen)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-ed15c706365e7c6ed5a4cbd212b5e968 wp-block-paragraph\"><a href=\"https:\/\/www.herlevhospital.dk\/undersoegelse-og-behandling\/find-undersoegelse-og-behandling\/Sider\/Erlotinib---Tarceva-behandling-med-23401.aspx\" target=\"_blank\" rel=\"noreferrer noopener\">Erlotinib &#8211; Tarceva, behandling med<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(Herlev Hospital)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-147b04574c6a259df2465966316caaa4 wp-block-paragraph\"><a href=\"https:\/\/aalborguh.rn.dk\/-\/media\/SXI\/KKKA21-104-Behandling-med-Tarceva\/KKKA21-104-pdf.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Behandling med Tarceva<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(\u00c5lborg Universitetshospital)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-cef9cdc17932bf45259e47506b122ae5 wp-block-paragraph\"><a href=\"https:\/\/www.cancer.gov\/research\/progress\/discovery\/gleevec\" target=\"_blank\" rel=\"noreferrer noopener\">How Imatinib Transformed Leukemia Treatment and Cancer Research<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(National Cancer Institute)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-1dafc9a7c31cfada7902cfd391430b66 wp-block-paragraph\"><a href=\"https:\/\/pro.medicin.dk\/medicin\/praeparater\/4369\" target=\"_blank\" rel=\"noreferrer noopener\">Tasigna<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(Medicin.dk)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-1f1dc54a0f5bbfe25d17edfa2dac92c2 wp-block-paragraph\"><a href=\"https:\/\/www.herlevhospital.dk\/undersoegelse-og-behandling\/find-undersoegelse-og-behandling\/Sider\/Tasgina-Nilotinib-behandling-med-23585.aspx\" target=\"_blank\" rel=\"noreferrer noopener\">Tasgina (Nilotinib), behandling med<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(Herlev Hospital)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-08fe5976b9a832a7b22200c87623d2b6 wp-block-paragraph\"><a href=\"https:\/\/www.herlevhospital.dk\/undersoegelse-og-behandling\/find-undersoegelse-og-behandling\/Sider\/Nexavar-Sorafenib-behandling-med-23580.aspx\" target=\"_blank\" rel=\"noreferrer noopener\">Nexavar (Sorafenib), behandling med<\/a> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(Herlev Hospital)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-98b01ce8c896ac5fbbdc98eed3b6df01 wp-block-paragraph\"><strong><a href=\"https:\/\/www.sst.dk\/udgivelser\/2006\/sunitinib-sutent-til-behandling-af-nyrecellekraeft\" target=\"_blank\" rel=\"noopener\">Sunitinib (Sutent) til behandling af nyrecellekr\u00e6ft<\/a><\/strong> <mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-sort-tekst-color\">(Sundhedsstyrelsen)<\/mark><\/p>\n\n\n\n<p class=\"has-custom-bl-links-color has-text-color has-link-color wp-elements-0af1ad3e27379b3e52ee25755e467ed1 wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Siden oprettet:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">d. 23.12.24 (bearbejdet)<a href=\"https:\/\/jegharkraeft.dk\/dr-vogl\"><\/a><\/p>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-menu-links-color\">\u2764<\/mark><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hvad du l\u00e6ser p\u00e5 <\/strong><em><strong>Jeg har Kr\u00e6ft<\/strong><\/em><strong> er ikke en anbefaling. S\u00f8g kompetent vejledning.<\/strong><\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-group alignfull is-style-default has-global-padding is-layout-constrained wp-container-core-group-is-layout-b040ace0 wp-block-group-is-layout-constrained has-background\" style=\"margin-top:0;margin-bottom:0;padding-top:var(--wp--preset--spacing--60);padding-right:var(--wp--preset--spacing--20);padding-bottom:var(--wp--preset--spacing--60);padding-left:var(--wp--preset--spacing--20);background-image:url(&apos;http:\/\/jegharkraeft.dk\/wp-content\/uploads\/2025\/02\/bTyrosinkinasehaemmere.jpg&apos;);background-position:44% 36%;background-size:cover;\">\n<div class=\"gb-element-421c682e\">\n<h2 class=\"wp-block-heading\" id=\"tyrosinkinasehaemmer-statistik\"><span class=\"ez-toc-section\" id=\"Tyrosinkinasehaemmere_%E2%80%93_Statistik\"><\/span>Tyrosinkinaseh\u00e6mmere &#8211;<br>Statistik<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Herunder omtales:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Crizotinib (Xalkori)<\/li>\n\n\n\n<li>Dasatinib (Sprycel)<\/li>\n\n\n\n<li>Erlotinib (Tarceva)<\/li>\n\n\n\n<li>(Gefitinib (Iressa))<\/li>\n\n\n\n<li>Imatinib (Gleevec)<\/li>\n\n\n\n<li>(Lapatinib (Tykerb))<\/li>\n\n\n\n<li>Nilotinib (Tasigna)<\/li>\n\n\n\n<li>Sorafenib (Nexavar)<\/li>\n\n\n\n<li>Sunitinib (Sutent)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Statistikker-2\"><\/span><strong>Statistikker<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Disse statistikker er baseret p\u00e5 gennemsnitlige resultater fra store grupper af patienter. Den individuelle effekt af tyrosinkinaseh\u00e6mmere kan variere betydeligt afh\u00e6ngigt af kr\u00e6fttype, stadie, patientens generelle sundhedstilstand og andre faktorer.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bem\u00e6rk<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">De n\u00e6vnte tal herunder stammer fra Gemini Advanced. Jeg har ingen mulighed for at tjekke p\u00e5lideligheden. Men den er s\u00e6dvanligvis p\u00e5lidelig.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Bed altid om at f\u00e5 de relevante statistikker for din konkrete kr\u00e6fttype, kr\u00e6ftform og den behandling du anbefales<\/strong><a href=\"https:\/\/jegharkraeft.dk\/parp-haemmere#parphaemmerstatistiktekst\">.<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Her vises nogle generelle statistikker og eksempler p\u00e5 studier, der viser effekten af tyrosinkinaseh\u00e6mmere i behandlingen af forskellige kr\u00e6ftformer:<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Imatinib_Gleevec\"><\/span>Imatinib (Gleevec)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kronisk myeloid leuk\u00e6mi (CML):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>10-\u00e5rs overlevelsesrate: Over 90%.<\/li>\n\n\n\n<li>IRIS-studiet: 8-\u00e5rs overlevelsesrate p\u00e5 83%.<\/li>\n\n\n\n<li>Signifikant reduktion i risikoen for progression til accelereret fase eller blastkrise (under 10% med Imatinib vs. 30-50% f\u00f8r)<\/li>\n\n\n\n<li>Bivirkninger: Kvalme, opkastning, diarr\u00e9, muskelsmerter, v\u00e6skeretention.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>F\u00f8rstelinjebehandling af GIST:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>GIST ((GastroIntestinal Stromal Tumor) er en sj\u00e6lden form for kr\u00e6ft, der opst\u00e5r i mave-tarmkanalen).<\/li>\n\n\n\n<li>Signifikant forbedret overlevelse hos patienter med metastatisk GIST (median overlevelse over 5 \u00e5r med Imatinib vs. ca. 1 \u00e5r f\u00f8r).<\/li>\n\n\n\n<li>Bivirkninger: Kvalme, opkastning, diarr\u00e9, muskelsmerter.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Dasatinib_Sprycel\"><\/span>Dasatinib (Sprycel)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kronisk myeloid leuk\u00e6mi (CML):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Effektiv hos patienter, der er resistente eller intolerante over for Imatinib.<\/li>\n\n\n\n<li>DASISION-studiet: H\u00f8jere andel af patienter opn\u00e5ede st\u00f8rre molekyl\u00e6r respons (MMR) sammenlignet med Imatinib (85,7% vs. 66,1% efter 2 \u00e5r).<\/li>\n\n\n\n<li>Bivirkninger: Pleural effusion (v\u00e6skeansamling omkring lungerne), bl\u00f8dning, hovedpine.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Nilotinib_Tasigna\"><\/span>Nilotinib (Tasigna)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Kronisk myeloid leuk\u00e6mi (CML):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Effektiv hos patienter, der er resistente eller intolerante over for Imatinib.<\/li>\n\n\n\n<li>ENESTnd-studiet: H\u00f8jere andel af patienter opn\u00e5ede st\u00f8rre molekyl\u00e6r respons sammenlignet med Imatinib (44% vs. 22% opn\u00e5ede MR4.5 efter 12 m\u00e5neder).<\/li>\n\n\n\n<li>Bivirkninger: Kardiovaskul\u00e6re h\u00e6ndelser, forh\u00f8jet blodsukker, pancreatitis (bet\u00e6ndelse i bugspytkirtlen).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Gefitinib_Iressa\"><\/span>Gefitinib (Iressa)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Lungekr\u00e6ft:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Forbedret progressionsfri overlevelse hos patienter med avanceret lungekr\u00e6ft med EGFR-mutationer.<\/li>\n\n\n\n<li>IPASS-studiet: Gefitinib var mere effektiv end kemoterapi hos patienter med EGFR-mutationer (median PFS 9,5 m\u00e5neder vs. 6,3 m\u00e5neder).<\/li>\n\n\n\n<li>Bivirkninger: Hudreaktioner, diarr\u00e9, levertoksicitet.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Erlotinib_Tarceva\"><\/span>Erlotinib (Tarceva)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Lungekr\u00e6ft:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Forbedret overlevelse hos patienter med avanceret lungekr\u00e6ft med EGFR-mutationer.<\/li>\n\n\n\n<li>BR.21-studiet: Erlotinib forbedrede overlevelsen sammenlignet med placebo (median overlevelse 6,7 m\u00e5neder vs. 4,7 m\u00e5neder).<\/li>\n\n\n\n<li>Bivirkninger: Hudreaktioner, diarr\u00e9, tr\u00e6thed.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Afatinib_Giotrif\"><\/span>Afatinib (Giotrif)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Lungekr\u00e6ft:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Effektiv hos patienter med avancerede EGFR-mutationspositive NSCLC, inklusive dem med T790M-resistensmutationen.<\/li>\n\n\n\n<li>LUX-Lung studierne: Afatinib forbedrede progressionsfri overlevelse sammenlignet med kemoterapi (median PFS 11,1 m\u00e5neder vs. 6,9 m\u00e5neder i LUX-Lung 3).<\/li>\n\n\n\n<li>Bivirkninger: Hudreaktioner, diarr\u00e9, stomatitis (bet\u00e6ndelse i mundslimhinden).<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sunitinib_Sutent\"><\/span>Sunitinib (Sutent)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nyrekr\u00e6ft:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Forbedret overlevelse hos patienter med metastatisk RCC (median overlevelse 26,4 m\u00e5neder vs. 14,6 m\u00e5neder for interferon alfa).<\/li>\n\n\n\n<li>Bivirkninger: H\u00e5nd-fod-syndrom, hypertension (forh\u00f8jet blodtryk), hypothyreoidisme (nedsat stofskifte).<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Behandling af resistent GIST:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Anvendes i behandlingen af GIST, der er resistent over for Imatinib.<\/li>\n\n\n\n<li>Bivirkninger: H\u00e5nd-fod-syndrom, hypertension, hypothyreoidisme.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Pazopanib_Votrient\"><\/span>Pazopanib (Votrient)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Nyrekr\u00e6ft:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Forbedret progressionsfri overlevelse hos patienter med metastatisk RCC (renalcellecarcinom).<\/li>\n\n\n\n<li>COMPARZ-studiet: Pazopanib viste sammenlignelig effektivitet med Sunitinib, men med en bedre sikkerhedsprofil.<\/li>\n\n\n\n<li>Median progressionsfri overlevelse (PFS):<\/li>\n\n\n\n<li>Pazopanib: 8,4 m\u00e5neder<\/li>\n\n\n\n<li>Sunitinib: 9,5 m\u00e5neder<\/li>\n\n\n\n<li>Selvom sunitinib viste en lidt l\u00e6ngere PFS, var forskellen ikke statistisk signifikant.<\/li>\n\n\n\n<li>Samlet overlevelse: Der var ingen signifikant forskel i samlet overlevelse mellem de to grupper.<\/li>\n\n\n\n<li>Sikkerhedsprofil: Pazopanib viste en bedre sikkerhedsprofil end sunitinib, med f\u00e6rre patienter, der oplevede alvorlige bivirkninger (grad 3 eller 4).<\/li>\n\n\n\n<li>For eksempel var forekomsten af h\u00e5nd-fod-syndrom (en almindelig bivirkning ved TKI&#8217;er) signifikant lavere med pazopanib (16%) end med sunitinib (29%).<\/li>\n\n\n\n<li>Bivirkninger: Diarr\u00e9, hypertension, h\u00e5rtab.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sorafenib_Nexavar-2\"><\/span>Sorafenib (Nexavar)<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hepatocellul\u00e6rt carcinom:<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Anvendes i behandlingen af avanceret RCC og hepatocellul\u00e6rt carcinom (leverkr\u00e6ft)<\/li>\n\n\n\n<li>Forbedret overlevelse hos patienter med avanceret hepatocellul\u00e6rt carcinom (median overlevelse 10,7 m\u00e5neder vs. 7,9 m\u00e5neder for placebo).<\/li>\n\n\n\n<li>Bivirkninger: H\u00e5nd-fod-syndrom, diarr\u00e9, hypertension.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Konklusion-2\"><\/span><strong>Konklusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Tyrosinkinaseh\u00e6mmere (TKI&#8217;er) har revolutioneret behandlingen af en r\u00e6kke kr\u00e6ftformer, herunder kronisk myeloid leuk\u00e6mi (CML), gastrointestinale stromale tumorer (GIST), lungekr\u00e6ft og nyrekr\u00e6ft. Studier har vist, at disse l\u00e6gemidler kan forbedre overlevelsen og livskvaliteten for patienter med disse sygdomme. For eksempel har Imatinib (Gleevec) \u00f8get 10-\u00e5rs overlevelsesraten for CML til over 90%, og forbedret median overlevelsen for metastatisk GIST til over 5 \u00e5r. Andre TKI&#8217;er, s\u00e5som Dasatinib (Sprycel), Nilotinib (Tasigna), Gefitinib (Iressa), Erlotinib (Tarceva), Afatinib (Giotrif), Sunitinib (Sutent), Pazopanib (Votrient) og Sorafenib (Nexavar), har ogs\u00e5 vist sig at v\u00e6re effektive i behandlingen af forskellige kr\u00e6ftformer. Det er dog vigtigt at huske, at TKI&#8217;er kan have bivirkninger, og at de ikke er effektive for alle patienter. Valget af TKI afh\u00e6nger af kr\u00e6fttypen, patientens individuelle karakteristika og eventuelle tidligere behandlinger.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>Resistens<\/strong><\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Kr\u00e6ftceller kan udvikle resistens over for tyrosinkinaseh\u00e6mmere over tid.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Denne information er kun til generel viden og erstatter ikke professionel medicinsk r\u00e5dgivning. Det er altid vigtigt at tale med din l\u00e6ge om din specifikke situation og behandling.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Se ogs\u00e5 <a href=\"https:\/\/jegharkraeft.dk\/hormonterapi\">Hormonbehandling<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Se ogs\u00e5 <a href=\"https:\/\/jegharkraeft.dk\/antioestrogen-naturligt\">Naturlige antihormoner<\/a><\/p>\n\n\n\n<p class=\"has-custom-menu-links-color has-text-color has-link-color wp-elements-6c90a65472076766d071fb4dda4759fa wp-block-paragraph\"><strong><a href=\"https:\/\/jegharkraeft.dk\/tyrosinkinasehaemmere#tyrosinkinasehaemmermenu\"><\/a><a href=\"#menu\">(til menu)<\/a><\/strong><\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Links<\/h4>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-bc9fb597e8bb89ba7c88efab5c4a53f9 wp-block-paragraph\"><a href=\"https:\/\/www.google.com\/search?q=Tyrosinkinaseh%C3%A6mmer&amp;rlz=1C1ONGR_enDK1116DK1116&amp;oq=Tyrosinkinaseh%C3%A6mmer&amp;gs_lcrp=EgZjaHJvbWUyCQgAEEUYORiABDIHCAEQABiABDIKCAIQABiABBiiBDIKCAMQABiABBiiBDIGCAQQRRg90gEHNDkyajBqN6gCALACAA&amp;sourceid=chrome&amp;ie=UTF-8\" target=\"_blank\" rel=\"noreferrer noopener\">Tyrosinkinaseh\u00e6mmere \u00f8ger risikoen for QTc-forl\u00e6ngelse<\/a> (Ugeskrift for L\u00e6ger)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-c74bdced2710a06a34f57c9ce688a29d wp-block-paragraph\"><a href=\"https:\/\/dagensmedicin.dk\/tyrosinkinasehaemmer-forlaenger-progressionsfri-overlevelse-ved-sjaeldne-neuroendokrine-tumorer\/\" target=\"_blank\" rel=\"noreferrer noopener\">Tyrosinkinaseh\u00e6mmer forl\u00e6nger progressionsfri overlevelse ved sj\u00e6ldne neuroendokrine tumorer<\/a> (Dagens Medicin)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-43a8b06e72d74901610bcb3ad288747c wp-block-paragraph\"><a href=\"https:\/\/netdoktor.dk\/kraeft\/leukaemi\/sygdomme\/medicinsk-behandling-af-cml-kronisk-myeloid-leukami\/\" target=\"_blank\" rel=\"noreferrer noopener\">Medicinsk behandling af CML (kronisk myeloid leuk\u00e6mi) <\/a>(Netdoktor.dk)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-60fd04a72b1cc4876ba3b168b95eaaaa wp-block-paragraph\"><a href=\"https:\/\/www.herlevhospital.dk\/undersoegelse-og-behandling\/find-undersoegelse-og-behandling\/Sider\/Crizotinib---Xalkori-behandling-med--23411.aspx\" target=\"_blank\" rel=\"noreferrer noopener\">Crizotinib &#8211; Xalkori, behandling med<\/a> (Herlev Hospital)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-c21e0d9214593a43db8156be1df52ffd wp-block-paragraph\"><a href=\"https:\/\/laegemiddelstyrelsen.dk\/da\/nyheder\/2022\/xalkori-crizotinib-synsforstyrrelser,-herunder-risiko-for-alvorligt-synstab,-og-behov-for-monitorering-hos-paediatriske-patienter\/\" target=\"_blank\" rel=\"noreferrer noopener\">Xalkori (crizotinib): Synsforstyrrelser, herunder risiko for alvorligt synstab, og behov for monitorering hos p\u00e6diatriske patienter<\/a> (L\u00e6gemiddelstyrelsen)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-afb3c058b1047647d7cd33c7b0425e79 wp-block-paragraph\"><a href=\"https:\/\/min.medicin.dk\/medicin\/praeparater\/4089\" target=\"_blank\" rel=\"noreferrer noopener\">Sprycel<\/a> (Medicin.dk)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-a4951c88d8e1b68e55340cf6384ff0c5 wp-block-paragraph\"><a href=\"https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160715135210\/anx_135210_da.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Dasatinib &#8211; SPRYCEL, INN<\/a> (European Commission)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-2916b92acc4a415f0a76626a2ea9ba04 wp-block-paragraph\"><a href=\"https:\/\/xnet.dkma.dk\/indlaegsseddel\/PdfFileServlet?formulationid=6534&amp;lang=da\" target=\"_blank\" rel=\"noreferrer noopener\">Dasatinib &#8211; Sprycel, INN<\/a> (L\u00e6gemiddelstyrelsen)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-f413fd14f44002fbc9274907cd5d3aed wp-block-paragraph\"><a href=\"https:\/\/www.herlevhospital.dk\/undersoegelse-og-behandling\/find-undersoegelse-og-behandling\/Sider\/Erlotinib---Tarceva-behandling-med-23401.aspx\" target=\"_blank\" rel=\"noreferrer noopener\">Erlotinib &#8211; Tarceva, behandling med<\/a> (Herlev Hospital)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-14deaecedf5d8489c4c721767f2cf165 wp-block-paragraph\"><a href=\"https:\/\/aalborguh.rn.dk\/-\/media\/SXI\/KKKA21-104-Behandling-med-Tarceva\/KKKA21-104-pdf.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Behandling med Tarceva<\/a> (\u00c5lborg Universitetshospital)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-f7c764bdc787672301cbaea5ac8eac6c wp-block-paragraph\"><a href=\"https:\/\/www.cancer.gov\/research\/progress\/discovery\/gleevec\" target=\"_blank\" rel=\"noreferrer noopener\">How Imatinib Transformed Leukemia Treatment and Cancer Research<\/a> (National Cancer Institute)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-75cdba483d27493c16ed31be27606e4f wp-block-paragraph\"><a href=\"https:\/\/pro.medicin.dk\/medicin\/praeparater\/4369\" target=\"_blank\" rel=\"noreferrer noopener\">Tasigna<\/a> (Medicin.dk)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-aee6490d1619867913bef8ad4c45be2d wp-block-paragraph\"><a href=\"https:\/\/www.herlevhospital.dk\/undersoegelse-og-behandling\/find-undersoegelse-og-behandling\/Sider\/Tasgina-Nilotinib-behandling-med-23585.aspx\" target=\"_blank\" rel=\"noreferrer noopener\">Tasgina (Nilotinib), behandling med<\/a> (Herlev Hospital)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-1d9d8cb80baa2aba3be0080c3061ab63 wp-block-paragraph\"><a href=\"https:\/\/www.herlevhospital.dk\/undersoegelse-og-behandling\/find-undersoegelse-og-behandling\/Sider\/Nexavar-Sorafenib-behandling-med-23580.aspx\" target=\"_blank\" rel=\"noreferrer noopener\">Nexavar (Sorafenib), behandling med<\/a> (Herlev Hospital)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-4be2b353c1dd8c7c99c7b981be3d3211 wp-block-paragraph\"><a href=\"https:\/\/www.sst.dk\/udgivelser\/2006\/sunitinib-sutent-til-behandling-af-nyrecellekraeft\" target=\"_blank\" rel=\"noopener\">Sunitinib (Sutent) til behandling af nyrecellekr\u00e6ft <\/a>(Sundhedsstyrelsen)<\/p>\n\n\n\n<p class=\"has-custom-sort-tekst-color has-text-color has-link-color wp-elements-2b0963c5de7d07142fbb8ea6898ea14b wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Siden oprettet:<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">d. 23.12.24<\/p>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-custom-menu-links-color\">\u2764<\/mark><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Hvad du l\u00e6ser p\u00e5 <\/strong><em><strong>Jeg har Kr\u00e6ft<\/strong><\/em><strong> er ikke en anbefaling. S\u00f8g kompetent vejledning.<\/strong><\/p>\n<\/div>\n<\/div>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_83 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Indhold<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Behandlinger\" >Behandlinger<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-1'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Tyrosinkinasehaemmere_%E2%80%93_Laegemiddelbehandling_mod_kraeft\" >Tyrosinkinaseh\u00e6mmere &#8211; L\u00e6gemiddelbehandling mod kr\u00e6ft<\/a><ul class='ez-toc-list-level-2' ><li class='ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Tyrosinkinasehaemmernes_molekylaere_mekanismer\" >Tyrosinkinaseh\u00e6mmernes molekyl\u00e6re mekanismer<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Signaltransduktionens_dirigenter\" >Signaltransduktionens dirigenter<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Signaltransduktion_og_kraeft\" >Signaltransduktion og kr\u00e6ft<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#TKIernes_indgriben_i_signaltransduktion\" >TKI&#8217;ernes indgriben i signaltransduktion<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Hvordan_virker_tyrosinkinasehaemmere\" >Hvordan virker tyrosinkinaseh\u00e6mmere<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Arsager_til_overaktivitet_af_tyrosinkinaser_i_kraeftceller\" >\u00c5rsager til overaktivitet af tyrosinkinaser i kr\u00e6ftceller:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Effekt_pa_kraeftceller\" >Effekt p\u00e5 kr\u00e6ftceller<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Effekt_pa_raske_celler\" >Effekt p\u00e5 raske celler<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Bivirkninger\" >Bivirkninger<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Almindelige_bivirkninger\" >Almindelige bivirkninger:<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Mindre_almindelige_men_alvorlige_bivirkninger\" >Mindre almindelige, men alvorlige bivirkninger<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Handtering_af_bivirkninger\" >H\u00e5ndtering af bivirkninger<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Resistensmekanismer\" >Resistensmekanismer<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Overvindelse_af_resistens\" >Overvindelse af resistens<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Typer_af_tyrosinkinasehaemmere\" >Typer af tyrosinkinaseh\u00e6mmere<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Eksempler_pa_tyrosinkinasehaemmere\" >Eksempler p\u00e5 tyrosinkinaseh\u00e6mmere<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#1_Imatinib_Gleevec\" >1. Imatinib (Gleevec)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#2_Gefitinib_Iressa_og_Erlotinib_Tarceva\" >2. Gefitinib (Iressa) og Erlotinib (Tarceva)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#3_Sunitinib_Sutent\" >3. Sunitinib (Sutent)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#4_Andre_TKIer\" >4. Andre TKI&#8217;er<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Dasatinib_Sprycel_og_Nilotinib_Tasigna\" >Dasatinib (Sprycel) og Nilotinib (Tasigna)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Sorafenib_Nexavar\" >Sorafenib (Nexavar)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Lapatinib_Tykerb\" >Lapatinib (Tykerb)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Crizotinib_Xalkori\" >Crizotinib (Xalkori)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Bemaerk\" >Bem\u00e6rk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-28\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Aspekter_ved_behandling\" >Aspekter ved behandling<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-29\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Konklusion\" >Konklusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-30\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Statistikker\" >Statistikker<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-31\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Tyrosinkinasehaemmere_%E2%80%93_Statistik\" >Tyrosinkinaseh\u00e6mmere &#8211; Statistik<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-32\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Statistikker-2\" >Statistikker<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-33\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Imatinib_Gleevec\" >Imatinib (Gleevec)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-34\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Dasatinib_Sprycel\" >Dasatinib (Sprycel)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-35\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Nilotinib_Tasigna\" >Nilotinib (Tasigna)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-36\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Gefitinib_Iressa\" >Gefitinib (Iressa)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-37\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Erlotinib_Tarceva\" >Erlotinib (Tarceva)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-38\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Afatinib_Giotrif\" >Afatinib (Giotrif)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-39\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Sunitinib_Sutent\" >Sunitinib (Sutent)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-40\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Pazopanib_Votrient\" >Pazopanib (Votrient)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-41\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Sorafenib_Nexavar-2\" >Sorafenib (Nexavar)<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-42\" href=\"https:\/\/jegharkraeft.dk\/en\/tyrosinkinasehaemmere\/#Konklusion-2\" >Konklusion<\/a><\/li><\/ul><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Behandlinger Traditionelle Behandlinger Oversigt 0. Traditionelle Behandlinger Alment Tyrosinkinaseh\u00e6mmere &#8211; L\u00e6gemiddelbehandling mod kr\u00e6ft Herunder omtales: Hvad er Tyrosinkinaseh\u00e6mmere Tyrosinkinaseh\u00e6mmere (TKI&#8217;er) repr\u00e6senterer en milep\u00e6l inden for kr\u00e6ftbehandling, der tilbyder en mere m\u00e5lrettet og pr\u00e6cis tilgang til at bek\u00e6mpe kr\u00e6ft. De virker ved at blokere aktiviteten af tyrosinkinaser, en familie af enzymer, der spiller en kritisk rolle [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4389,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[150,18,143,22],"tags":[],"class_list":["post-5022","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-maalrettet-terapi","category-behandlinger","category-laegemiddelbehandling","category-traditionelle-behandlinger"],"modified_by":"Hanne","wpml_current_locale":"da_DK","wpml_translations":[],"_links":{"self":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/posts\/5022","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/comments?post=5022"}],"version-history":[{"count":0,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/posts\/5022\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/media\/4389"}],"wp:attachment":[{"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/media?parent=5022"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/categories?post=5022"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jegharkraeft.dk\/en\/wp-json\/wp\/v2\/tags?post=5022"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}